# Combination of Sotyktu and Enstilar for Plaque Psoriasis

> **NCT06329258** · PHASE4 · COMPLETED · sponsor: **Psoriasis Treatment Center of Central New Jersey** · enrollment: 30 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Enstilar
- **DRUG:** Deucravacitinib

## Key facts

- **NCT ID:** NCT06329258
- **Lead sponsor:** Psoriasis Treatment Center of Central New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-06
- **Primary completion:** 2023-11-13
- **Final completion:** 2023-11-13
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06329258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06329258, "Combination of Sotyktu and Enstilar for Plaque Psoriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06329258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*